Quality of Life Index for Atopic Dermatitis

The Quality of Life Index for Atopic Dermatitis (QoLIAD) is a disease specific patient reported outcome which measures the impact that atopic dermatitis (AD) has on a given patient's quality of life.[1]

It is a 25-item questionnaire for patients over the age of 16[2] with a maximum score of 25 and is restricted to yes or no answers.[3] Higher scores on the QoLIAD indicate a greater negative influence that the disease has on quality of life.[4]

## Development[edit]

The QoLIAD was developed in 2004 and funded by Novartis Pharma AG, Switzerland. It was produced in several countries and the content was derived from 65 qualitative interviews with patients in the UK, Italy and Netherlands. The initial version of the measure was produced in UK English and it was then translated for the Netherlands, Italy, Germany, France and the US. A Spanish version was then later developed. Further tests were implemented to validate the measure and it was administrated to 300 patients in each country to finalize the instrument.[5]

The institutions involved in the development of the QoLIAD are: Galen Research (United Kingdom), Erasmus University (The Netherlands), University of Greifswald (Germany), University of Verona (Italy), C.H.U Bichat (France), 3D Health Research (Spain) and Novartis Pharmaceuticals Corporation (USA).[5]

## International use[edit]

The QoLIAD has been translated into seven languages other than UK English.[6] They include German, Spanish and Japanese.

The QoLIAD has also been utilized to assess the effectiveness of new treatments of atopic dermatitis. This includes studies looking into educational intervention,[4][7] topical corticosteroids[8] and pimecrolimus.[9]

## References[edit]

1. ^ Meads, D.M.; McKenna, S.P.; Doward, L.C.; Hampson, N.; McGeown, C. (May 2005). "Psk6 Interpreting Scores on the Quality of Life Index for Atopic Dermatitis (Qoliad)". Value in Health. 8 (3): 331–332. doi:10.1016/S1098-3015(10)62870-7. Retrieved 28 October 2013.
2. ^ Ehlken, B.; Kugland, B; Schramm, B; Quednau, K; Berger, K. (November 2003). "Psn12 Quality-Of-Life in Patients Suffering from Atopic Dermatitis in Germany". Value in Health. 6 (6): 787–788. doi:10.1016/S1098-3015(10)62005-0. Retrieved 28 October 2013.
3. ^ Ashcroft, D.M.; Chen, L.C.; Garside, R.; Stein, K.; Williams, H.C. (2007). Ashcroft, Darren M (ed.). "Topical pimecrolimus for eczema (Review)". Cochrane Database of Systematic Reviews (4): CD005500. doi:10.1002/14651858.CD005500.pub2. PMID 17943859.
4. ^ a b Lambert, J.; Bostoen, J.; Geusens, B.; Bourgois, J.; Boone, J.; De Smedt, D.; Annemans, L. (January 2011). "A novel multidisciplinary educational programme for patients with chronic skin diseases: Ghent pilot project and first results". Archives of Dermatological Research. 303 (1): 57–63. doi:10.1007/s00403-010-1082-z. PMID 20842368. S2CID 20817434.
5. ^ a b Whalley, D.; McKenna, S.P.; Dewar, A.L.; Erdman, R.A.; Kohlmann, T.; Niero, M.; Cook, S.A.; Crickx, B.; Herdman, M.J.; Frech, F.; Van Assche, D. (2004). "A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD)". British Journal of Dermatology. 150 (2): 274–283. doi:10.1111/j.1365-2133.2004.05783.x. PMID 14996098. S2CID 23271179.
6. ^ "Measures Database". Galen-Research.com. Galen Research. Retrieved 28 October 2013.
7. ^ Bostoen, J.; Bracke, S.; De Keyser, S.; Lambert, J. (Nov 2012). "An educational programme for patients with psoriasis and atopic dermatitis: a prospective randomized controlled trial". The British Journal of Dermatology. 167 (5): 1025–1031. doi:10.1111/j.1365-2133.2012.11113.x. PMID 22709422. S2CID 11139439.
8. ^ Moed, Heleen; Yang, Quan; Oranje, Arnold P.; Panda, Saumya; van der Wouden, Johannes C. (2012). Moed, Heleen (ed.). "Different strategies for using topical corticosteroids for established eczema". Cochrane Database of Systematic Reviews (10). doi:10.1002/14651858.CD010080. (Retracted, see doi:10.1002/14651858.cd010080.pub2. If this is an intentional citation to a retracted paper, please replace `{{Retracted}}` with `{{Retracted|intentional=yes}}`.)
9. ^ Lecomte, P.; Lambert, J.; Degreef, H.; Lesaffre, E.; De Backer, M. (November 2006). "PSK6 BELGIAN DRUG UTILISATION STUDY OF ELIDEL® IN ROUTINE PRACTICE IN ATOPIC DERMATITIS". Value in Health. 9 (6): A268. doi:10.1016/S1098-3015(10)63408-0. Retrieved 28 October 2013.